These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
184 related items for PubMed ID: 1279965
1. Finasteride for benign prostatic hyperplasia. Hasinski S, Miller JL, Rose LI. Am Fam Physician; 1992 Nov; 46(5):1511-4. PubMed ID: 1279965 [Abstract] [Full Text] [Related]
2. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GL, Geller J, Bracken BR, Tenover JS. N Engl J Med; 1992 Oct 22; 327(17):1185-91. PubMed ID: 1383816 [Abstract] [Full Text] [Related]
3. New options for patients with benign prostatic hyperplasia. Ellenberger B. CMAJ; 1993 Feb 15; 148(4):543-7. PubMed ID: 7679313 [No Abstract] [Full Text] [Related]
4. One-year experience in the treatment of benign prostatic hyperplasia with finasteride. The MK-906 (Finasteride) Study Group. J Androl; 1991 Feb 15; 12(6):372-5. PubMed ID: 1722792 [Abstract] [Full Text] [Related]
5. Finasteride: the first 5 alpha-reductase inhibitor. Sudduth SL, Koronkowski MJ. Pharmacotherapy; 1993 Feb 15; 13(4):309-25; discussion 325-9. PubMed ID: 7689728 [Abstract] [Full Text] [Related]
7. Thoughts on finasteride for benign prostatic hyperplasia. Anand A. Am Fam Physician; 1993 Sep 15; 48(4):582, 588. PubMed ID: 7691035 [No Abstract] [Full Text] [Related]
8. Is the prostate pill finally here? Lange PH. N Engl J Med; 1992 Oct 22; 327(17):1234-6. PubMed ID: 1383817 [No Abstract] [Full Text] [Related]
9. Finasteride for benign prostatic hypertrophy. Med Lett Drugs Ther; 1992 Sep 04; 34(878):83-4. PubMed ID: 1380630 [No Abstract] [Full Text] [Related]
10. [5-alpha reductase inhibitor in prostatic adenoma?]. Heinzl S. Med Monatsschr Pharm; 1990 Dec 04; 13(12):382-4. PubMed ID: 1705307 [No Abstract] [Full Text] [Related]
11. [Effect of dutasteride on reduction of plasma DHT following finasteride therapy in patients with benign prostatic hyperplasia]. Botto H, Lan O, Poulain JE, Comenducci A. Prog Urol; 2005 Dec 04; 15(6):1090-5. PubMed ID: 16429658 [Abstract] [Full Text] [Related]
14. The clinical development of a 5 alpha-reductase inhibitor, finasteride. Stoner E. J Steroid Biochem Mol Biol; 1990 Nov 20; 37(3):375-8. PubMed ID: 1701660 [Abstract] [Full Text] [Related]
15. Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen. Geller J. J Clin Endocrinol Metab; 1990 Dec 20; 71(6):1552-5. PubMed ID: 1699965 [Abstract] [Full Text] [Related]
16. Effects of long term treatment with finasteride (MK-906), a 5-alpha reductase inhibitor, on circulating LH, FSH, prolactin and estradiol. Matzkin H, Chen J, Lewyshon O, Ayalon D, Braf Z. Horm Metab Res; 1992 Oct 20; 24(10):498-9. PubMed ID: 1281461 [No Abstract] [Full Text] [Related]
18. [Prostatic adenoma: new drugs, new surgical techniques]. Heinzl S. Med Monatsschr Pharm; 1992 Dec 20; 15(12):362-4. PubMed ID: 1282201 [No Abstract] [Full Text] [Related]
20. A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 alpha-reductase inhibitors GI198745 and finasteride. Gisleskog PO, Hermann D, Hammarlund-Udenaes M, Karlsson MO. Clin Pharmacol Ther; 1998 Dec 20; 64(6):636-47. PubMed ID: 9871428 [Abstract] [Full Text] [Related] Page: [Next] [New Search]